ALVR vs. PASG, CRIS, PLX, ATHA, GRTS, JATT, ELUT, DTIL, OTLK, and CGTX
Should you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Passage Bio (PASG), Curis (CRIS), Protalix BioTherapeutics (PLX), Athira Pharma (ATHA), Gritstone bio (GRTS), JATT Acquisition (JATT), Elutia (ELUT), Precision BioSciences (DTIL), Outlook Therapeutics (OTLK), and Cognition Therapeutics (CGTX). These companies are all part of the "biological products, except diagnostic" industry.
Passage Bio (NASDAQ:PASG) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.
Passage Bio currently has a consensus price target of $9.00, suggesting a potential upside of 571.64%. AlloVir has a consensus price target of $18.50, suggesting a potential upside of 2,362.07%. Given Passage Bio's higher probable upside, analysts plainly believe AlloVir is more favorable than Passage Bio.
In the previous week, Passage Bio had 9 more articles in the media than AlloVir. MarketBeat recorded 15 mentions for Passage Bio and 6 mentions for AlloVir. AlloVir's average media sentiment score of 0.87 beat Passage Bio's score of 0.07 indicating that Passage Bio is being referred to more favorably in the media.
AlloVir's return on equity of -73.12% beat Passage Bio's return on equity.
Passage Bio has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.
Passage Bio received 21 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 66.67% of users gave Passage Bio an outperform vote while only 57.45% of users gave AlloVir an outperform vote.
Passage Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.
53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 66.1% of AlloVir shares are owned by institutional investors. 4.3% of Passage Bio shares are owned by insiders. Comparatively, 33.8% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Passage Bio beats AlloVir on 10 of the 15 factors compared between the two stocks.
Get AlloVir News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
